Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
16.08.2026 08:00
Assembly Biosciences' key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC. Read why ASMB stock is a Buy.
Why Gilead Sciences (GILD) Is Back In The Spotlight
13.08.2026 09:11
Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder returns are above 90%...
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
13.08.2026 04:21
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O’Day highlighted, “Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,” underscoring the im
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
07.08.2026 14:00
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
06.08.2026 11:04
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...
05.08.2026 05:06
Gilead delivers strongest Q2 base business growth in 3 years, raises full-year HIV guidance, and showcases rapid uptake of Yeztugo and Trodelvy despite acquisition-related EPS drag.
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance
05.08.2026 00:37
Gilead Q2 beats estimates but stock slips as full-year guidance disappoints, with heavy acquisition charges offsetting strong HIV and Trodelvy sales.
Gilead Sciences Q2 Earnings Call Highlights
05.08.2026 00:04
Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and incre
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?
04.08.2026 15:19
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
04.08.2026 12:00
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on finan
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
30.07.2026 13:15
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
30.07.2026 13:00
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run
30.07.2026 07:08
Gilead Sciences stock has delivered a strong 130.1% return over the past 5 years, which raises a clear question for investors about how much value is already reflected in the current US$132.73 share price. The latest valuation checks paint a mixed picture, with some signals pointing to the shares screening as undervalued while others are more cautious. Over 5 years, Gilead Sciences has returned 130.1%. This puts current buyers in the position of assessing whether that long run of gains still...
Gilead: Buy The Distortion Before Q2 Clears It Up
30.07.2026 06:55
Gilead Sciences HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Read why GILD stock is a buy.
Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value Debate
30.07.2026 04:27
Gilead Sciences (GILD) is back in focus after regulators in Europe issued a positive opinion on expanding Trodelvy’s use alongside Keytruda for certain advanced triple negative breast cancer patients. See our latest analysis for Gilead Sciences. Alongside the positive Trodelvy opinion, Gilead Sciences shares have seen a 5.07% 30 day share price return and a 9.15% year to date share price return, while the 5 year total shareholder return of 130.07% reflects strong longer term compounding. If...
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
28.07.2026 12:27
Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
28.07.2026 11:00
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided an update on the development of opaganib1 for Ebola virus disease (EVD) as the number of confirmed Bundibugyo ebolavirus (BDBV) cases and deaths has increased substantially to 3221 cases and 1407 deaths2.
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
28.07.2026 10:13
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.
Kalshi is expanding online betting in drug R&D — unless detractors can stop it
28.07.2026 09:48
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
24.07.2026 11:10
Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.